<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1239">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04466839</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/20/0193</org_study_id>
    <nct_id>NCT04466839</nct_id>
  </id_info>
  <brief_title>Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients</brief_title>
  <acronym>ERCO-Park</acronym>
  <official_title>Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The consequences of COVID-19 in these already fragile patients should be evaluated. It will
      be important to appreciate the confinement consequences imposed on the patient on the course
      and impact of the disease.

      These consequences can be assessed by the end of confinement and 6 months after the latter is
      lifted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adaptation capacities are necessary to cope with the brutal and drastic changes imposed by
      the pandemic and its consequences. In Parkinson's disease, where there are routine situations
      with difficulties adjusting to newness, patients in the current situation may be particularly
      affected and present anxiety due to great difficulties in adaptation.

      The repercussions in terms of symptoms (motor and non-motor) of the disease could be very
      significant. In this population already widely exposed to anxio-depressive symptoms
      (depression being a common symptom of Parkinson's disease, affecting up to 30 to 40% of
      patients outside of crisis periods), we can expect a risk increased psychiatric
      decompensation. The psychiatric consequences could not be limited to the current period but
      also concern long-term patients, in particular if there is decompensation of other symptoms
      of the disease (motors, complications linked to treatment, etc.).

      The consequences of COVID-19 in these already fragile patients should be evaluated. It will
      be important to appreciate the confinement consequences imposed on the patient on the course
      and impact of the disease.

      These consequences can be assessed by the end of confinement and 6 months after the latter is
      lifted.

      This is an observational, French multicenter study, of an uncontrolled cohort of parkinsonian
      patients followed by doctors from Parkinson Expert Centers in hospitals.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2, 2020</start_date>
  <completion_date type="Anticipated">December 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of containment related to the Covid-19 pandemic.</measure>
    <time_frame>6 months after the end of the pandemic</time_frame>
    <description>To compare quality of life using Parkinson Disease Questionnaire-8 Items (PDQ-8 ), during the period of confinement linked to the Covid-19 pandemic and 6 months after the end of the pandemic in patients with idiopathic Parkinson's disease.
The minimum value is &quot;never&quot; and maximum value is &quot;always&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conditions of containment during the Covid-19 pandemic.</measure>
    <time_frame>Day 1</time_frame>
    <description>Describe in a cohort of Parkinson's patients the conditions of confinement during the confinement period linked to the Covid-19 pandemic such as lifestyle (patient living alone, patient living with a caregiver, patient living in nursing home) and continuing paramedical care (physiotherapist, speech therapist), thanks to a psychosocial assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients infected or possibly infected with Covid-19</measure>
    <time_frame>6 months after the end of the pandemic</time_frame>
    <description>Infected patients will be defined as having had a positive polymerase chain reaction (PCR) or compatible chest scanner. Patients potentially infected: patients who presented symptoms during the period which could suggest an infection by the Covid-19 virus: cough, fever and dyspnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms modifications</measure>
    <time_frame>6 months after the end of the pandemic</time_frame>
    <description>Patients will be asked to list the 3 main symptoms that have changed during the confinement period</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>parkinsonian patients</arm_group_label>
    <description>Cohort of parkinsonian patients followed by doctors from the Parkinson Expert Centers in teaching hospitals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire and interview</intervention_name>
    <description>The questionnaires are Parkinson Disease Questionnaire-8 Items (PDQ-8) Visual Analog Scale (VAS) is visual analog scale visual numeric from 0 to 100, Neuropsychiatric Inventory-Questionnaire-Reduced (NPI-R) and Clinical Global Impression-Impairment (CGI-I).</description>
    <arm_group_label>parkinsonian patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient followed by a doctor from the Parkinson Expert Center with idiopathic Parkinson's
        disease between 16/03/2020 and 16/05/2020.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient followed by a doctor from the Parkinson Expert Center of the Toulouse
             University Hospital, Lille, Paris, Rouen, Nimes, Reims, Besancon, Marseille

          -  And with idiopathic Parkinson's disease

          -  Patients hospitalized or in consultation between 16/03/2020 and 16/05/2020.

        Exclusion Criteria:

          -  Atypical parkinsonian syndrome

          -  Patient subject to a legal protection order (tutorship)

          -  Patient not wishing to answer questions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabienne ORY MAGNE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Delphine Vernet</last_name>
    <phone>5 61 77 72 16</phone>
    <phone_ext>+33</phone_ext>
    <email>vernet.d@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabienne ORY MAGNE</last_name>
    <phone>5 61 77 25 35</phone>
    <phone_ext>+33</phone_ext>
    <email>ory.f@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Régionale Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthieu Bereau</last_name>
      <email>mbereau@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Luc Defevbre</last_name>
      <phone>3 20 44 67 30</phone>
      <phone_ext>+33</phone_ext>
      <email>Luc.defebvre@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nicolas Carriere</last_name>
      <phone>3 20 44 67 52</phone>
      <phone_ext>+33</phone_ext>
      <email>nicolas.carriere@chru-lille.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fréderique Fluchere</last_name>
      <phone>4 91 38 43 33</phone>
      <phone_ext>+33</phone_ext>
      <email>Frederique.fluchere@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Tatiana Witjas</last_name>
      <phone>4 91 38 43 33</phone>
      <phone_ext>+33</phone_ext>
      <email>Tatiana.WITJAS@ap-hm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nîmes - Caremeau</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie De Verdal</last_name>
    </contact>
    <contact_backup>
      <phone>4 66 68 32 61</phone>
      <phone_ext>+33</phone_ext>
      <email>marie.deverdal@chu-nimes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de la Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Grabli David</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Doé de Maindreville</last_name>
      <phone>3 26 78 78 78</phone>
      <phone_ext>+33</phone_ext>
      <email>adoedemaindreville@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>David Maltête</last_name>
      <phone>2 32 95 10 31</phone>
      <phone_ext>+33</phone_ext>
      <email>David.Maltete@chu-rouen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Céline Bergot</last_name>
      <phone>2 32 88 57 81</phone>
      <phone_ext>+33</phone_ext>
      <email>Celine.Bergot@chu-rouen.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Delphine Vernet</last_name>
      <phone>5 61 77 86 03</phone>
      <phone_ext>+33</phone_ext>
      <email>vernet.d@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Delphine Vernet</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease,</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Confinement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

